Cue Biopharma vs Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is the larger business, with $49.8m of revenue in fiscal 2025 against $27.5m for Cue Biopharma (1.8 times as much). Cue Biopharma grew faster (195.7% against 60.2%). Cue Biopharma kept more of each dollar of sales as profit: a net margin of -96.9% against -101.1%.
| Latest fiscal year | Cue BiopharmaCUE, 2025 | Lexicon PharmaceuticalsLXRX, 2025 |
|---|---|---|
| Revenue | $27.5m | $49.8m |
| Revenue growth | 195.7% | 60.2% |
| Net income | −$26.6m | −$50.3m |
| Operating margin | — | -98.2% |
| Net margin | -96.9% | -101.1% |
| Return on equity | -121.1% | -39.7% |
| Free cash flow | −$21.9m | −$67.9m |
| Cash | $27.1m | $34.3m |
| Total debt | — | $54.0m |
| Debt to equity | — | 50.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 29 | — |
| Market value | $106m | $652m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 26 (Weak) |
| Insider trades, 12 months | 5 buys, 15 sales | 8 buys, 0 sales |